BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

NCT04162353 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma in Relapse
Refractory Multiple Myeloma
Plasmacytoid; Lymphoma

Interventions

BIOLOGICAL: BCMA-CD19 cCAR T cells

Sponsor

iCell Gene Therapeutics

Collaborators

[object Object]
[object Object]